Skip to main content

Endometrial Cancer Screening

Unlike breast or cervical cancer, no routine screening is recommended for endometrial cancer in average-risk individuals.[1][2][3] Early detection relies on symptom awareness and prompt evaluation of abnormal uterine bleeding, particularly postmenopausal bleeding. Screening is considered only in specific high-risk hereditary cancer syndromes, and even there evidence of a mortality benefit from surveillance is lacking.

All major societies agree that evidence is insufficient to recommend screening for endometrial cancer in average-risk women, including those with common risk factors such as obesity, tamoxifen use, late menopause, nulliparity, or diabetes.[1][3]

The primary recommendation is patient education: at the onset of menopause, all individuals with a uterus should be informed about the risks and symptoms of endometrial cancer and strongly encouraged to report any unexpected vaginal bleeding or spotting immediately.[4][1] This approach is supported by the fact that 75–90% of endometrial cancers present with abnormal vaginal bleeding, and most are diagnosed at an early stage with favorable prognosis.[5][3]

Why population-based screening has not been adopted​

Several factors explain the absence of a population-level screening program:[2][6]

Favorable natural history. Most endometrial cancers present symptomatically at stage I, with 5-year survival rates exceeding 88%. A mortality benefit is difficult to demonstrate in a cancer with a generally good prognosis.[2]

Transvaginal ultrasound (TVUS) limitations. TVUS has insufficient diagnostic accuracy for asymptomatic screening. Thickness cutoffs can produce both missed disease and unnecessary procedures. TVUS is not recommended for premenopausal screening due to normal cyclical variation in endometrial thickness.[6][2][8][3]

Endometrial biopsy is invasive. Office sampling may be painful or insufficient.

No proven mortality reduction. No screening modality has demonstrated a reduction in endometrial cancer mortality in any population studied, including high-risk groups.[2][9]

Diagnostic evaluation of symptomatic patients​

  • ACOG April 2026 update. ACOG recommends both TVUS and endometrial tissue sampling in the initial evaluation of most patients with postmenopausal bleeding.[23] TVUS alone may be used after one bleeding episode when the endometrium is fully visualized at 4 mm or less, strong endometrial-cancer risk factors are absent, prompt follow-up is feasible, and the patient is counseled to return immediately for continued or recurrent bleeding.[39]
  • In a retrospective study of 1,494 Black patients who underwent hysterectomy, 20 of the 210 with endometrial cancer (9.5%) had endometrial thickness <4 mm, showing that this threshold missed cancer in the selected cohort.[5][35]
  • Persistent or recurrent bleeding. Histologic evaluation (endometrial biopsy) is warranted regardless of endometrial thickness, because aggressive subtypes cannot be excluded by thickness alone.[5]
  • Office endometrial sampling is a diagnostic option, with further directed evaluation when results are insufficient or discordant or symptoms persist. A 2023 accuracy review included 12 studies (1,607 participants); its three Pipelle studies estimated sensitivity at 77.4% (95% CI 56.5–90.0%) and specificity at 98.5% (92.7–99.7%) against hysterectomy histology.[24]
  • In premenopausal women, no single endometrial-thickness cutoff reliably excludes cancer. TVUS still helps evaluate structural causes of abnormal bleeding; sampling depends on age, risk factors, persistence and response to treatment.[5][3][29]

High-risk populations: hereditary cancer syndromes​

Surveillance is considered only in specific hereditary syndromes, though evidence of mortality benefit remains limited.

Lynch syndrome​

Lynch syndrome increases endometrial-cancer risk, but the estimate depends strongly on the gene, age horizon and study. Estimates differ between database reports, particularly for MSH6 and PMS2.[25]

GeneApproximate EC risk by age 70
MLH135%
MSH246%
MSH641%
PMS213%
EPCAMDeletion-dependent

For patients retaining a uterus, discuss endometrial sampling every one to two years, commonly beginning around age 30–35, while acknowledging unproven survival benefit. Education and prompt evaluation of bleeding are still needed; prophylactic surgery and surveillance should be individualized with genetics and gynecologic oncology.[9][25]

Surveillance limitations and decisions:[8]

  • Endometrial cancer screening has no proven benefit in patients with Lynch syndrome. Endometrial biopsy is highly sensitive and specific as a diagnostic procedure and can be considered.
  • TVUS. TVUS is not recommended as a screening tool in premenopausal patients. In postmenopausal patients, TVUS has not been shown to be sufficiently sensitive or specific to support a positive recommendation, but may be considered at clinician discretion.
  • Symptom education. Patients must be counseled to report any abnormal uterine or postmenopausal bleeding promptly.
  • Total hysterectomy. Hysterectomy has not been shown to reduce EC mortality, but it reduces EC incidence and is a risk-reducing option to discuss after completion of childbearing.

ACOG Practice Bulletin No. 147 similarly recommends endometrial biopsy every 1–2 years starting at age 30–35 for LS carriers, noting that one cited surveillance study found poor sensitivity for transabdominal or transvaginal ultrasonography in detecting endometrial cancer.[9] The US Multi-Society Task Force on Colorectal Cancer concurs with annual pelvic examination and endometrial sampling starting at age 30–35 (level V evidence, GRADE low quality).[7]

Cowden syndrome (PTEN hamartoma tumor syndrome)​

PHTS carries increased endometrial-cancer risk; among the 281 females in a 455-person adult PHTS cohort, risk after excluding cancer index cases was estimated at 22.1% by age 60, while the incident-case analysis estimated 6.4% from age 50 onward.[38] The July 2026 ERN GENTURIS guideline discusses substantial ascertainment bias and a cohort estimate of 33% by age 70 after excluding index cases.[26]

Guidelines vary on asymptomatic surveillance. The 2025 international consensus recommends education about abnormal uterine bleeding at PHTS diagnosis or age 30–35, weakly recommends both TVUS and endometrial biopsy for unexplained or irregular bleeding after age 30–35, and confines routine surveillance, if offered, to a clinical trial.[27] The 2026 ERN GENTURIS guideline says women with a germline PTEN pathogenic variant should probably undergo endometrial surveillance from age 35–40, with TVUS at least annually if offered and biopsy considered; risk-reducing hysterectomy may be discussed individually.[26] The 2025 consensus does not recommend routine risk-reducing hysterectomy in PHTS . Uterine and ovarian decisions should be discussed separately with the genetics and gynecologic team.[10][26][27]

Other hereditary cancer syndromes​

The ACS also recommends considering annual endometrial testing starting at age 35 for women with a substantial likelihood of carrying a Lynch syndrome mutation or families with suspected autosomal dominant predisposition to colorectal cancer, even without confirmed genetic testing. ACS states that this recommendation rests on expert opinion.[1]

Risk factors​

Risk factorRelative riskNotes
Increasing BMI (obesity: BMI ≥30)RR 1.59 per 5-unit BMI increase among womenOverweight and obesity account for up to 50% of EC cases[15][3]
Unopposed estrogen therapy4–8×Markedly attenuated by progestogen opposition[11]
Tamoxifen use2–3×Dose/duration and menopausal status affect risk; counsel about endometrial cancer and uterine sarcoma[22]
Later versus earlier menopause age (highest vs lowest study categories)RR 1.89Prolonged estrogen exposure[11][33]
Nulliparity~2×First full-term pregnancy was associated with 22% lower EC odds versus none; each additional full-term pregnancy after the first with ~15% lower odds[5][34]
Diabetes / insulin resistance2×Independent of obesity[11]
Lynch syndromeGene- and age-specificSee age-70 estimates above[5]
PTEN hamartoma tumor syndromeIncreased; ascertainment-sensitiveSee current guideline discussion above[10]
Prior pelvic irradiationIn SEER rectal- and bladder-cancer cohorts, 20-year secondary uterine-cancer incidence with versus without radiotherapy was 2.59% versus 0.84% and 1.46% versus 0.41%, respectively.[40]Among 205 irradiated versus 1,001 nonirradiated patients who developed second endometrial cancer after pelvic-organ cancer, tumors were poorly differentiated in 58% versus 28%.[41]
PCOS / chronic anovulation~3×Prolonged unopposed estrogen[11]

Protective factors: oral contraceptive use for 10–<15 years (RR 0.52) or ≥15 years (RR 0.32) versus never use, with the inverse association persisting >30 years after cessation[37]; ever IUD use (pooled OR 0.81 versus never use)[28]; parity; and physical activity.[11][5][2]

Risk reduction strategies​

Hormonal and pharmacologic​

  • Combined oral contraceptives. In high-income countries, ten years of use was estimated to be associated with a lower absolute EC risk before age 75, from 2.3 to 1.3 per 100 women.[37] In a three-month randomized biomarker trial of 51 asymptomatic women with Lynch syndrome (46 completed treatment), both oral contraceptives and depot medroxyprogesterone lowered endometrial epithelial proliferation and produced progestin-type histology.[5][12][42]
  • Levonorgestrel IUS. The levonorgestrel IUS has a role in selected management of endometrial hyperplasia or fertility-sparing cancer care under specialist surveillance. The pooled OR of 0.81 (95% CI 0.74–0.90) in that consortium analysis concerned ever use of any IUD; among seven studies reporting device type, the estimate for hormone-releasing devices was 0.97 (95% CI 0.44–2.14; 21 exposed cases and 12 exposed controls).[28][13]
  • Aspirin. In the CAPP2 randomized trial in Lynch syndrome (600 mg daily), aspirin reduced colorectal cancer (HR 0.65, 95% CI 0.43–0.97), but the intention-to-treat analysis found no demonstrated reduction in non-colorectal Lynch cancers (36 participants in each arm).[30] A pooled analysis of 7,120 EC cases found that at least weekly aspirin use was associated with approximately 15% lower risk in overweight or obese women (OR 0.86), with no association in normal-weight women.[14]
  • Metformin. Theoretical value through insulin sensitization, but no prospective trial data yet support primary prevention use.[2]

Surgical​

  • Risk-reducing hysterectomy is the most definitive prevention strategy for LS carriers. Timing is individualized by gene, family history, and reproductive goals (see Lynch syndrome table above).[8] Before preventive surgery, the 2026 ESGO consensus recommends endometrial biopsy and pelvic ultrasound to assess for occult gynecologic cancer, especially when symptoms are present (level IV evidence, grade B).[31]
  • Bariatric surgery was associated with lower EC odds than nonsurgical controls among women with obesity in a systematic review of five observational studies (OR 0.32, 95% CI 0.16–0.63).[5][36]

Lifestyle​

Obesity is the main modifiable risk factor and accounts for up to 50% of endometrial cancers in some estimates.[15] Physical activity is associated with lower risk independent of weight.[15][3]

Tamoxifen-specific considerations​

ACOG advises against routine endometrial surveillance in asymptomatic tamoxifen users unless a separate high-risk situation has been identified.[22]

  • The commonly cited 2–3-fold relative risk comes chiefly from postmenopausal tamoxifen cohorts; the absolute endometrial-cancer risk in older trials was low, and ACOG does not recommend routine surveillance in asymptomatic users.[22] Premenopausal risk remains uncertain: in a 2026 observational cohort, the per-protocol analysis found an association, while the intention-to-treat confidence interval included 1.[32]
  • Any abnormal vaginal bleeding in a tamoxifen user should be promptly evaluated
  • Counsel about polyps, hyperplasia, endometrial cancer and uterine sarcoma
  • If atypical hyperplasia develops, coordinate gynecologic management and reassessment of tamoxifen with the breast-care team[22]

Emerging screening technologies​

No novel screening tool is currently recommended for clinical use. Several approaches are under study:[2][16][17]

  • DNA methylation markers from cervicovaginal samples. In the EPI-SURE prospective UK cohort of 399 women with abnormal bleeding (12 cancers), the WID-qEC test (methylation of ZSCAN12 and GYPC) had an AUC of 94.3% among 378 with an evaluable test and final diagnosis versus 87.2% for endometrial thickness on ultrasound among 369 (p = 0.48).[6] A separate three-gene methylation panel (ZNF626, GRIA4, SPDYA) detected 26 of 28 stage-I cancers (92.86%) in an 80-sample cervical-cytology validation set.[18]
  • Liquid biopsy. Serum exosomal piRNA panels and plasma-derived exosomal miRNAs (e.g., miR-15a-5p) have shown AUCs of 0.81–0.94 for EC detection in early studies.[19][20]
  • Protein biomarkers. In prediagnostic plasma from the EPIC nested case-control study, HE4 had limited discrimination for EC diagnosed within 12 months of blood collection (AUC 0.76); adding other proteins did not meaningfully improve performance.[21]
  • Integration with cervical cancer screening. DNA methylation testing on routine Pap smear samples could be incorporated into existing cervical screening infrastructure without a separate screening visit.[17][18]

These technologies remain investigational and require prospective validation before clinical implementation.

See Also​

References​

1. Smith RA, Andrews KS, Brooks D, et al. "Cancer Screening in the United States, 2019: A Review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening." CA Cancer J Clin. 2019;69(3):184–210. doi:10.3322/caac.21557

2. Crosbie EJ, Kitson SJ, McAlpine JN, et al. "Endometrial Cancer." Lancet. 2022;399(10333):1412–1428. doi:10.1016/S0140-6736(22)00323-3

3. Bryce C, Gazda R, Fuerst H. "Endometrial Cancer: Rapid Evidence Review." Am Fam Physician. 2025;111(6):526–531. PMID 40531151

4. American Cancer Society. "American Cancer Society Guidelines for the Early Detection of Cancer." American Cancer Society; 2023. https://www.cancer.org

5. Mager KL, McLean K. "Endometrial Cancer: A Review." JAMA. 2026;335(18):1616–1627. doi:10.1001/jama.2026.2248

6. Evans I, Reisel D, Jones A, et al. "Performance of the WID-qEC Test Versus Sonography to Detect Uterine Cancers in Women With Abnormal Uterine Bleeding (EPI-SURE): A Prospective, Consecutive Observational Cohort Study in the UK." Lancet Oncol. 2023;24(12):1375–1386. doi:10.1016/S1470-2045(23)00466-7

7. Giardiello FM, Allen JI, Axilbund JE, et al. "Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer." Gastroenterology. 2014;147(2):502–526. doi:10.1053/j.gastro.2014.04.001

8. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. Updated 2025-06-13. https://www.nccn.org

9. American College of Obstetricians and Gynecologists. "ACOG Practice Bulletin No. 147: Lynch Syndrome." Obstet Gynecol. 2014;124(5):1042–1054. doi:10.1097/01.AOG.0000456325.50739.72

10. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Updated 2026-02-19. https://www.nccn.org

11. Lu KH, Broaddus RR. "Endometrial Cancer." N Engl J Med. 2020;383(21):2053–2064. doi:10.1056/NEJMra1514010

12. Chen LM, Blank SV, Burton E, et al. "Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review." Fertil Steril. 2019;112(6):1034–1042. doi:10.1016/j.fertnstert.2019.07.1349

13. MacKintosh ML, Crosbie EJ. "Prevention Strategies in Endometrial Carcinoma." Curr Oncol Rep. 2018;20(12):101. doi:10.1007/s11912-018-0747-1

14. Webb PM, Na R, Weiderpass E, et al. "Use of Aspirin, Other Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen and Risk of Endometrial Cancer: The Epidemiology of Endometrial Cancer Consortium." Ann Oncol. 2019;30(2):310–316. doi:10.1093/annonc/mdy541

15. Shen S, Brown KA, Green AK, Iyengar NM. "Obesity and Cancer: A Translational Science Review." JAMA. 2026;335(15):1341–1350. doi:10.1001/jama.2026.1114

16. Fatahichegeni M, Haji Ghasem Sharbatdar Z, Ansarian MA. "Advances in Endometrial Cancer Screening: A Comprehensive Review of Current Methods and Emerging Technologies." Int J Clin Oncol. 2025. doi:10.1007/s10147-025-02941-9

17. Asaturova A, Zaretsky A, Rogozhina A, Tregubova A, Badlaeva A. "Advancements in Minimally Invasive Techniques and Biomarkers for the Early Detection of Endometrial Cancer: A Comprehensive Review of Novel Diagnostic Approaches and Clinical Implications." J Clin Med. 2024;13(24):7538. doi:10.3390/jcm13247538

18. Cai Y, Chen S, Wu Z, et al. "Systematic Multiplatform Discovery of Methylation Markers Enables Non-Invasive Early Detection of Endometrial Cancer." Cancer Sci. 2026. doi:10.1111/cas.70346

19. Zhang T, Zhang P, Zhu L, et al. "Unlocking the Potential of Serum Exosomal PIWI-interacting RNAs as Diagnostic Biomarker for Endometrial Cancer." Int J Gynecol Cancer. 2026;36(5):104659. doi:10.1016/j.ijgc.2026.104659

20. Zhou L, Wang W, Wang F, et al. "Plasma-Derived Exosomal miR-15a-5p as a Promising Diagnostic Biomarker for Early Detection of Endometrial Carcinoma." Mol Cancer. 2021;20(1):57. doi:10.1186/s12943-021-01352-4

21. Cooley V, Fortner RT, Mukama T, et al. "Prospective Evaluation of 92 Protein Biomarkers for Early Detection of Endometrial Cancer." Int J Cancer. 2025;157(3):480–489. doi:10.1002/ijc.35428

22. American College of Obstetricians and Gynecologists. Tamoxifen and Uterine Cancer. Committee Opinion, 2014. Official guidance.

23. ACOG. Updated Guidance on Evaluation of Postmenopausal Bleeding. April 16, 2026. Official announcement.

24. Sakna NA, Elgendi M, Salama MH, et al. "Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis." BMJ Open. 2023;13(6):e072124. doi:10.1136/bmjopen-2023-072124

25. Idos G, Valle L. Lynch Syndrome. GeneReviews. Updated 2021. Chapter and gene-specific risk table.

26. Hoogerbrugge N, et al. ERN GENTURIS cancer surveillance guideline for individuals with PTEN hamartoma tumour syndrome (PHTS). Eur J Hum Genet. 2026. doi:10.1038/s41431-026-02181-z.

27. Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group. 2025. Full consensus recommendations.

28. Felix AS, Gaudet MM, La Vecchia C, et al. "Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium." Int J Cancer. 2015;136(5):E410–E422. doi:10.1002/ijc.29229

29. ACR. Appropriateness Criteria: Abnormal Uterine Bleeding. 2020. Official criteria.

30. Burn J, Sheth H, Elliott F, et al. "Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial." Lancet. 2020;395(10240):1855–1863. doi:10.1016/S0140-6736(20)30366-4

31. Marchetti C, Gultekin M, Sassu CM, et al. "ESGO consensus statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome." Eur J Cancer. 2026;240:116739. doi:10.1016/j.ejca.2026.116739

32. Yeh YC, Chen PC, Huang HY, Chang CY. "Tamoxifen use and risk of uterine diseases in young women with breast cancer." Obstet Gynecol. 2026;147(5):725–734. doi:10.1097/AOG.0000000000006238

33. Wu Y, Sun W, Liu H, Zhang D. "Age at Menopause and Risk of Developing Endometrial Cancer: A Meta-Analysis." Biomed Res Int. 2019;2019:8584130. doi:10.1155/2019/8584130

34. Jordan SJ, Na R, Weiderpass E, et al. "Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium." Int J Cancer. 2021;148(9):2068–2078. doi:10.1002/ijc.33360

35. Doll KM, Pike M, Alson J, et al. "Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals." JAMA Oncol. 2024;10(8):1068–1076. doi:10.1001/jamaoncol.2024.1891

36. Winder AA, Kularatna M, MacCormick AD. "Does Bariatric Surgery Affect the Incidence of Endometrial Cancer Development? A Systematic Review." Obes Surg. 2018;28(5):1433–1440. doi:10.1007/s11695-018-3151-x

37. Collaborative Group on Epidemiological Studies on Endometrial Cancer. "Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27,276 women with endometrial cancer from 36 epidemiological studies." Lancet Oncol. 2015;16(9):1061–1070. doi:10.1016/S1470-2045(15)00212-0

38. Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, et al. "Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome." J Natl Cancer Inst. 2023;115(1):93–103. doi:10.1093/jnci/djac188

39. American College of Obstetricians & Gynecologists. "Updated guidance regarding the role of transvaginal ultrasonography in evaluating the endometrium of individuals with postmenopausal bleeding." Obstet Gynecol. 2026;148(1):e87–e91. doi:10.1097/AOG.0000000000006275

40. Yuan Q, Xing X, Ma Z, Shang P, Tang Z, Yue J. "Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine cancers: a SEER analysis." Radiother Oncol. 2026;222:111697. doi:10.1016/j.radonc.2026.111697

41. Kumar S, Shah JP, Bryant CS, et al. "Radiation-associated endometrial cancer." Obstet Gynecol. 2009;113(2 Pt 1):319–325. doi:10.1097/AOG.0b013e3181954c5b

42. Lu KH, Loose DS, Yates MS, et al. "Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome." Cancer Prev Res (Phila). 2013;6(8):774–781. doi:10.1158/1940-6207.CAPR-13-0020